Overview

  • Product nameAnti-PTEN antibody [Y184]See all PTEN primary antibodies ...
  • Description
    Rabbit monoclonal [Y184] to PTEN
  • SpecificityIHC has been taken off due to inconsistent results in this application. Our apologies for the inconvenience. 25th of March 2011
  • Tested applicationsWB, Flow Cyt, IP, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to residues in the C-term of human PTEN.

  • Positive control
    • MCF7, Hela cell lysates, human thyroid gland carcinoma
  • General notes

    Produced under U.S. Patent No. 5,675,063.

    This product is available conjugated to DyLight® 488 see ab139832.

Properties

Applications

Our Abpromise guarantee covers the use of ab32199 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500. Detects a band of approximately 54 kDa (predicted molecular weight: 47 kDa).Can be blocked with PTEN peptide (ab157804). A 42kDa band is seen for some samples in addition to 50-54kDa band- we do not know the specificity of this band. For example Rat kidney, heart, spleen have bands around 50kDa but rat PC-12 cells have single band at ~42kDa.
Flow Cyt 1/20.
IP 1/50.
ICC/IF Use at an assay dependent dilution.

Target

  • FunctionTumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability.
  • Tissue specificityExpressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
  • Involvement in diseaseDefects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.
    Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.
    Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Myhre-Smith syndrome (RMSS) or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.
    Defects in PTEN are a cause of head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
    Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089].
    Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
    Defects in PTEN are a cause of susceptibility to glioma type 2 (GLM2) [MIM:613028]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas.
    Defects in PTEN are a cause of VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects.
    Defects in PTEN may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
    Defects in PTEN are a cause of macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).
    Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
  • Sequence similaritiesContains 1 C2 tensin-type domain.
    Contains 1 phosphatase tensin-type domain.
  • DomainThe C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
  • Post-translational
    modifications
    Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4.
    Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN comportmentalization.
  • Cellular localizationCytoplasm. Nucleus. Nucleus > PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies.
  • Information by UniProt
  • Database links
  • Alternative names
    • 10q23del antibody
    • Bannayan Zonana syndrome antibody
    • BZS antibody
    • DEC antibody
    • GLM2 antibody
    • ITGA 2 antibody
    • MGC11227 antibody
    • MHAM antibody
    • MMAC 1 antibody
    • MMAC1 antibody
    • MMAC1 antibody
    • MMAC1 phosphatase and tensin homolog deleted on chromosome 10 antibody
    • Multiple hamartoma (Cowden syndrome) antibody
    • Mutated in multiple advanced cancers 1 antibody
    • Mutated in Mutiple Advanced Cancers 1 antibody
    • Mutated in Mutiple Advanced Cancers 1 antibody
    • Phosphatase and Tensin Homolog antibody
    • Phosphatase and Tensin Homolog antibody
    • Phosphatase and tensin like protein antibody
    • Phosphatidylinositol 345 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN antibody
    • Phosphatidylinositol 345 trisphosphate 3 phosphatase antibody
    • Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN antibody
    • Platelet antigen BR antibody
    • PTEN 1 antibody
    • Pten antibody
    • PTEN_HUMAN antibody
    • PTEN1 antibody
    • Tensin homolog antibody
    • TEP 1 antibody
    • TEP1 antibody
    • TEP1 antibody
    • VLA 2 Receptor Alpha Subunit antibody
    see all

Anti-PTEN antibody [Y184] images

  • Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution + MCF7 cell lysate

    Predicted band size : 47 kDa
    Observed band size : 54 kDa (why is the actual band size different from the predicted?)
  • ab32199 staining PTEN in human white blood cells by Immunocytochemistry/ Immunofluorescence. The cells were acetone fixed then blocked using 1% BSA for 1 hour at 25°C. Samples were then incubated with primary antibody at a 1/100 dilution for 2 hours at 25°C. The secondary antibody used was a goat anti-rabbit IgG conjugated to Alexa Fluor® 488 (green) used at a 1/500 dilution. DAPI was used to stain the cell nuclei (blue).

    See Abreview

  • Overlay histogram showing MCF-7 cells stained with ab32199 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab32199, 1/20 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit monoclonal IgG (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in MCF-7 cells fixed with methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.

  • ICC/IF image of ab32199 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab32199, 1µg/ml) overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti-rabbit IgG - H&L, pre-adsorbed (ab96899) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution

    Lane 1 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 2 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 3 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 4 : Mouse primary bone marrow derived macrophage whole cell lysate

    Lysates/proteins at 50 µg per lane.

    Secondary
    HRP-conjugated goat anti-rabbit IgG polyclonal
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 47 kDa
    Observed band size : 50 kDa (why is the actual band size different from the predicted?)


    Exposure time : 30 seconds

    This image is courtesy of an anonymous Abreview

    Treatment:

    Lane 1 - control siRNA 24 hours

    Lane 2 - PTEN siRNA 24 hours

    Lane 3 - control siRNA 48 hours

    Lane 4 - PTEN siRNA 48 hours

    See Abreview

References for Anti-PTEN antibody [Y184] (ab32199)

This product has been referenced in:
  • Ngalame NN  et al. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol Sci 138:268-77 (2014). Read more (PubMed: 24431212) »
  • Hammond VE  et al. Ndfip1 Is Required for the Development of Pyramidal Neuron Dendrites and Spines in the Neocortex. Cereb Cortex N/A:N/A (2013). Read more (PubMed: 23897647) »

See all 15 Publications for this product

Product Wall

Application Western blot
Loading amount 50 µg
Gel Running Conditions Reduced Denaturing
Sample Mouse Cell lysate - whole cell (Primary bone marrow derived macrophage)
Specification Primary bone marrow derived macrophage
Treatment siRNA
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted May 28 2014

Sure, I'm happy to issue a credit for this. Your credit ID number is ***. Please let me know if you need anything else. Have a great weekend!

Thank you for contacting us. ab32199, anti-PTEN [Y184], has been develop to recognise the human PTEN, Uniprot reference P60484 http://www.uniprot.org/uniprot/P60484. ab104517, anti-PTEN1, has been develop to target the human PTEN1 prote...

Read More
Application Western blot
Sample Human Cell lysate - whole cell (Colon cell line)
Loading amount 80 µg
Specification Colon cell line
Gel Running Conditions Reduced Denaturing (3-8%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Dec 29 2010

Application Western blot
Sample Human Cell lysate - whole cell (Breast cancer cell lines)
Loading amount 20 µg
Specification Breast cancer cell lines
Gel Running Conditions Non-reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Username

Abcam user community

Verified customer

Submitted Dec 15 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (Bone marrow cells)
Specification Bone marrow cells
Fixative Methanol
Permeabilization No
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Dec 10 2010

Application Immunohistochemistry (Frozen sections)
Sample Rat Tissue sections (Brain)
Specification Brain
Fixative Formaldehyde
Permeabilization Yes - 0.1% Triton X-100
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Dec 09 2010

Application Western blot
Sample Mouse Tissue lysate - whole (muscle)
Loading amount 25 µg
Specification muscle
Gel Running Conditions Reduced Denaturing (10%)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Oct 28 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (WBC)
Specification WBC
Fixative Acetone
Permeabilization No
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Mar 25 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"